Complement Activation in the Treatment of B-Cell Malignancies

Unconjugated monoclonal antibodies (mAb) have revolutionized the treatment of B-cell malignancies. These targeted drugs can activate innate immune cytotoxicity for therapeutic benefit. mAb activation of the complement cascade results in complement-dependent cytotoxicity (CDC) and complement receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zent, Clive S., Pinney, Jonathan J., Chu, Charles C., Elliott, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709106/
https://www.ncbi.nlm.nih.gov/pubmed/33271825
http://dx.doi.org/10.3390/antib9040068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709106/
https://www.ncbi.nlm.nih.gov/pubmed/33271825
http://dx.doi.org/10.3390/antib9040068

Ejemplares similares